Author

J. D. Roback

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:proteomics· 3 Research Focus:host-pathogen & immune response· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:protein folding & dynamics· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Chandele· 2 shared A. Patel· 2 shared A. S. Neish· 2 shared A. Sharma· 2 shared C. Chakravarthy· 2 shared C. W. Davis· 2 shared E. S. Reddy· 2 shared F. Frank· 2 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Chandele

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response

A. Patel, S. Kumar, L. Lai, C. Chakravarthy, R. Valanparambil, E. S. Reddy, K. Gottimukkala, P. Bajpai, D. R. Raju, V. V. Edara, M. E. Davis-Gardner, S. Linderman, K. Dixit, P. Sharma, G. Mantus, , E. A. Ortlund

The paper identifies three monoclonal antibodies that poorly neutralize the Omicron BA.1 variant, revealing structural and molecular features of antibody evasion.

bioRxiv · Oct 24, 2022Immunology

Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody

S. Kumar, A. Patel, L. Lai, C. Chakravarthy, R. Valanparambil, M. E. Davis-Gardner, V. V. Edara, S. Linderman, E. S. Reddy, K. Gottimukkala, K. Nayak, P. Bajpai, V. Singh, F. Frank, N. Cheedarla, , A. Chandele

This paper identifies and structurally analyzes an antibody that neutralizes SARS-CoV-2 BA.1 and BA.2 variants, revealing its unique epitope and mechanism of action.

bioRxiv · May 13, 2022Immunology

Elevated SARS-CoV-2 Antibodies Distinguish Severe Disease in Early COVID-19 Infection

N. S. Haddad, D. C. Nguyen, M. E. Kuruvilla, A. Morrison-Porter, F. Anam, K. S. Cashman, R. P. Ramonell, S. Kyu, A. S. Saini, M. Cabrera-Mora, A. Derrico, D. Alter, J. D. Roback, M. Horwath, J. B. O'Keefe, , F. E.-H. Lee

This paper develops a multiplex immunoassay to measure SARS-CoV-2 antibody responses and finds that severe COVID-19 is associated with higher early antibody levels against S1 and N proteins.

bioRxiv · Dec 4, 2020 · PreprintImmunology